Introduction In a market filled with uncertainty, investors often overlook opportunities in sectors weighed down by volatility or recent setbacks. Mid-cap biotech firms, in particular, may look risky at first glance, but for those willing to dig deeper, some names present a strong recovery case.  Today, we examine two companies, one leading the way in gene-editing therapies, the other shaking up obesity drug development, that could offer outsized gains. Jane Davis, an analyst at Maverix-Global, will explore why patience and perspective matter when evaluating these beaten-down prospects. CRISPR Therapeutics: A Gene-Editing Pioneer Awaits Its Next Act CRISPR Therapeutics made history...

After months of relative calm, investors face a gauntlet of political deadlines and data releases that could jolt everything from Treasuries and the U.S. dollar to gold, corporate credit, and European bonds. From a looming U.S.–EU tariff decision to a contentious French budget vote, and another potential showdown in U.S.–China trade talks, risk premiums look thin compared with the hazards ahead.  Anna Tutova, chief market strategist at Maverix-Global, will unpack the hidden fault lines, outline where surprises may hit first, and explain which assets could swing most dramatically. Tariff Tremors on July 9 Risk desks are laser-focused on next week’s...

A sharp turn in US-China trade relations is reshaping the semiconductor landscape yet again. In a major shift, the US has lifted new export license requirements that had restricted Chinese buyers from accessing advanced chip design software.  The surprise decision follows an agreement to ease trade frictions in exchange for concessions on critical raw materials. A senior analyst at Prime Wealth now explores how this sudden policy reversal reveals bigger risks, hidden leverage, and the next questions facing global chipmakers. EDA Licenses: Imposed, Then Removed Just weeks ago, the US administration tightened its grip on tech exports, targeting electronic design...

Major changes could be ahead for one of America’s most famous media companies. As Paramount Global faces pressure from investors and regulators, a series of critical decisions and headline-grabbing controversies are shaping the company’s future.  Shareholders, legal experts, and market watchers are paying close attention to boardroom battles, a high-profile lawsuit settlement, and a multi-billion-dollar merger that could reshape the entertainment landscape. In this article, a senior financial broker from Markets Yield examines what’s at stake, breaking down the key developments and what they mean for Paramount and its investors. Shareholders Urged to Oppose Board Members Paramount Global is preparing...

Artificial intelligence has reached a new turning point. What was once the realm of research labs and experimental startups is now rapidly becoming a central focus for the world’s most influential companies.  This shift is not just about algorithms or data, but about business strategies, acquisitions, and the race to bring AI innovations into mainstream use. In this article, a senior financial analyst from Investitionsquorum unpacks the changing landscape, exploring how companies like Apple and Meta are redefining the future of AI in the corporate world. AI’s Value Rises, And So Do Its Stakes The numbers alone are striking. Anthropic,...